Abivax (ABVX) Cash & Equivalents (2021 - 2026)
Abivax (ABVX) recorded Cash & Equivalents of $450.99 million in Q2 2026, up 553.7% from $68.99 million a year earlier but down 19.3% from the prior quarter.
Abivax (ABVX) Cash & Equivalents (2021 - 2026) Analysis & Trends
At the end of FY2025, Abivax reported Cash & Equivalents of $583.76 million, up 274.0% from FY2024.
- Annual Cash & Equivalents has a four-year compound annual growth rate of 68.8% (FY2021 to FY2025).
- Across earlier years, Cash & Equivalents came in at $156.1 million in FY2024 (-42.7%), $272.53 million in FY2023 (+859.5%), $28.4 million in FY2022 (-60.5%) and $71.83 million in FY2021.
- Quarterly Cash & Equivalents has ranged from $27.5 million in Q4 2022 to $689.4 million in Q3 2025 over the past five years.
- On a year-over-year basis, Cash & Equivalents has increased for four consecutive quarters, with growth averaging 189.8% over the last seven quarters.
- Peak year-over-year performance for Cash & Equivalents in the last five years was growth of 885.9% in Q4 2023, against a decline of 74.6% in Q2 2025 at the low end.
- Per Business Quant, the preceding three quarters came in at $558.94 million (Q1 2026), $601.44 million (Q4 2025) and $689.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.54 Bn | 572.07 Bn | 17.26 Bn | 20.42 Bn |
| 2 | AbbVie | 467.01 Bn | 440.17 Bn | 12.70 Bn | 6.57 Bn |
| 3 | Merck | 367.16 Bn | 321.59 Bn | 12.21 Bn | 6.85 Bn |
| 4 | Novartis Ag | 277.56 Bn | 233.43 Bn | 11.24 Bn | 7.62 Bn |
| 5 | Astrazeneca | 258.23 Bn | 231.79 Bn | 12.86 Bn | 4.89 Bn |
| 6 | Amgen | 224.14 Bn | 179.54 Bn | 7.24 Bn | 13.99 Bn |
| 7 | Gilead Sciences | 187.30 Bn | 161.42 Bn | 6.22 Bn | 3.18 Bn |
| 8 | Pfizer | 163.47 Bn | 110.41 Bn | 10.94 Bn | 976.00 Mn |
| 9 | Vertex Pharmaceuticals | 133.31 Bn | 105.31 Bn | 2.84 Bn | 6.14 Bn |
| 10 | Abivax | 7.15 Bn | 7.15 Bn | - | 450.99 Mn |
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 450.99 Mn |
| Mar 31, 2026 | 558.94 Mn |
| Dec 31, 2025 | 601.44 Mn |
| Sep 30, 2025 | 689.40 Mn |
| Jun 30, 2025 | 68.99 Mn |
| Mar 31, 2025 | 108.95 Mn |
| Dec 31, 2024 | 154.11 Mn |
| Sep 30, 2024 | 198.17 Mn |
| Jun 30, 2024 | 271.31 Mn |
| Mar 31, 2024 | 262.47 Mn |
| Dec 31, 2023 | 271.07 Mn |
| Dec 31, 2022 | 27.50 Mn |
| Dec 31, 2021 | 69.44 Mn |
Abivax Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=ABVX&period=max&api_key=YOUR_API_KEY
import requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "ABVX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()
const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=ABVX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();